<DOC>
	<DOCNO>NCT03052738</DOCNO>
	<brief_summary>This study propose prospective observational cohort study evaluate quality life ( QOL ) child Central Nervous System ( CNS ) tumor family choose self-medicate marijuana-derived product undergo treatment Children 's Hospital Colorado ( CHCO ) .</brief_summary>
	<brief_title>Medical Marijuana Pediatric Central Nervous System Tumor Population</brief_title>
	<detailed_description>Children 's Hospital Colorado ( CHCO ) Center Cancer Blood Disorders ( CCBD ) national leader pediatric cancer therapy . The CHCO Neuro-Oncology program treat 90 % Coloradan child Central Nervous System ( CNS ) tumor large percentage child CNS tumor surround five state . Due advance therapy , approximately two-thirds child CNS tumor treat CHCO cure . Although medical marijuana legal decade Colorado , publicity around recent legalization general adult use , increase literature , anecdotal report patient terminal CNS tumor cure medical marijuana , prompt recent increase interest current CHCO patient family . There influx pediatric cancer patient family move Colorado obtain marijuana-based product self-medicate . In particular , influx family distant state seek marijuana child , often unbeatable , advanced CNS tumor . The Investigators administer PedsQLTM questionnaire diaries gather data regard use practice , method delivery , strain use , dose frequency , family financial impact enrol patient . The Investigators also collect peripheral blood sample evaluate evidence immuno-modulation cannabinoids patient may already immunocompromised ass blood cannabinoid level . This study provide novel exploratory data regard use pattern , impact family resource , potential clinical benefit harm associate grow marijuana use pediatric neuro-oncology population . Such information may guide future child afflict CNS tumor family make decision whether pursue cannabinoid treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Spinal Cord Neoplasms</mesh_term>
	<mesh_term>Spinal Neoplasms</mesh_term>
	<criteria>1 . Age &gt; 2 year &lt; 18 year time study enrollment . 2 . Parents/legal guardian ( ) complete questionnaire must sign consent . There age parameter parent/legal guardian ' participation study . 3 . Patients must diagnosis central nervous system ( brain spinal ) tumor 4 . Patients must ONE following : Undergoing diseasedirected therapy disease surveillance prescribe Pediatric NeuroOncology physicians CHCO Planning transfer medical care Pediatric NeuroOncology physicians CHCO outside facility Receiving palliative care service manage conjunction physician CHCO 5 . Interest marijuana use discuss patient parent . 6 . Patient use marijuana product synthetics last 14 day ( washout period 14 day permit interested participate study ) 1 . An exception rule patient take first dose within 72 hour sign consent . These patient eligible study without go washout period . 1 . Use ( plan use ) synthetic marijuana product sole cannabinoid therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>central nervous system ( brain spinal ) tumor</keyword>
</DOC>